Bioventus (NASDAQ:BVS) Posts Earnings Results, Beats Expectations By $0.06 EPS

Bioventus (NASDAQ:BVS) released its earnings results on Wednesday. The company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.09 by $0.06, FiscalAI reports. Bioventus had a net margin of 4.00% and a return on equity of 28.88%. The company had revenue of $132.09 million for the quarter. Bioventus updated its FY 2026 guidance to 0.750-0.790 EPS.

Here are the key takeaways from Bioventus’ conference call:

• Strong Q1 results — revenue $132M (+7%), Adjusted EBITDA $24M (+24%), and Adjusted EPS $0.15 (nearly double); company raised 2026 Adjusted EPS and cash-from-operations guidance and reaffirmed revenue guidance of $600–$610M.
• The company is accelerating investment in four growth drivers (PNS, PRP, Ultrasonics, International), with PNS receiving more than half of planned spend and a dedicated general manager (Megan Rosengarten) hired to scale the PNS business.
• Cash generation and balance sheet progress — cash from operations increased by ~$28M YoY, debt was reduced by $22M to $272M, and management expects net leverage <2x by end of Q2 2026, prioritizing debt paydown and capital optionality.
• Margin and earnings resilience — adjusted gross margin of 76% (+110 bps) and adjusted EBITDA margin of 18% (+260 bps); management expects to hold ~20% adjusted EBITDA margin for 2026 despite stepped-up investments.
• Q1 benefited from a one-time favorable rebate adjustment (and ~+$2M FX tailwind); management calls the rebate timing idiosyncratic and did not raise full-year revenue guidance, signaling some of the quarter’s upside may not recur.

Bioventus Stock Up 2.6%

Shares of Bioventus stock traded up $0.28 during midday trading on Wednesday, hitting $10.96. The company had a trading volume of 880,919 shares, compared to its average volume of 370,708. Bioventus has a 52-week low of $5.81 and a 52-week high of $11.20. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.19 and a current ratio of 1.70. The stock has a market capitalization of $910.91 million, a P/E ratio of 33.20 and a beta of 0.72. The company has a 50 day moving average of $9.23 and a 200 day moving average of $8.16.

Analysts Set New Price Targets

BVS has been the subject of a number of analyst reports. Cantor Fitzgerald raised Bioventus to a “strong-buy” rating in a research note on Wednesday, March 4th. Craig Hallum boosted their price objective on shares of Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, March 6th. Barrington Research raised their target price on Bioventus from $13.00 to $14.00 and gave the stock an “outperform” rating in a research note on Friday, March 6th. Finally, CJS Securities started coverage on Bioventus in a report on Friday, March 27th. They issued a “market outperform” rating and a $14.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $14.00.

Insiders Place Their Bets

In other Bioventus news, Director Michelle Mcmurry-Heath sold 12,000 shares of Bioventus stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $8.79, for a total value of $105,480.00. Following the completion of the sale, the director owned 44,997 shares of the company’s stock, valued at approximately $395,523.63. This trade represents a 21.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 33.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Bioventus

Hedge funds have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC grew its holdings in shares of Bioventus by 4.1% in the fourth quarter. Nantahala Capital Management LLC now owns 6,047,403 shares of the company’s stock worth $44,993,000 after acquiring an additional 236,741 shares during the period. Vanguard Group Inc. increased its position in shares of Bioventus by 4.4% during the 3rd quarter. Vanguard Group Inc. now owns 2,924,788 shares of the company’s stock valued at $19,567,000 after purchasing an additional 122,749 shares during the last quarter. Royce & Associates LP lifted its stake in shares of Bioventus by 15.6% in the 3rd quarter. Royce & Associates LP now owns 1,262,976 shares of the company’s stock worth $8,449,000 after purchasing an additional 170,900 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Bioventus by 1.8% in the fourth quarter. Geode Capital Management LLC now owns 1,120,238 shares of the company’s stock worth $8,337,000 after buying an additional 19,388 shares during the last quarter. Finally, State Street Corp grew its position in Bioventus by 1.7% during the fourth quarter. State Street Corp now owns 891,024 shares of the company’s stock valued at $6,629,000 after buying an additional 14,590 shares during the period. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.